Acumen Pharmaceuticals (ABOS) Receivables - Other (2020 - 2026)

Acumen Pharmaceuticals has disclosed Receivables - Other across 6 years of filings, most recently posting $1.0 million for Q2 2026.

• In Q2 2026, Receivables - Other rose 219.05% year-over-year to $1.0 million; the TTM figure through Jun 2026 stood at $1.0 million (up 219.05% YoY), while the FY2025 annual figure was $625000.0, up 81.16% from the prior year.
• Receivables - Other came in at $1.0 million for Q2 2026 at Acumen Pharmaceuticals, up from $772000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.0 million in Q2 2026 to a low of $106000.0 in Q2 2024.
• Average Receivables - Other over 4 years is $418636.4, with a median of $345000.0 recorded in 2024.
• Year-over-year, Receivables - Other jumped 41.42% in 2025 and surged 219.05% in 2026.
• Over 4 years, Receivables - Other stood at $225000.0 in 2023, then soared by 53.33% to $345000.0 in 2024, then jumped by 81.16% to $625000.0 in 2025, then jumped by 60.8% to $1.0 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.0 million in Q2 2026, $772000.0 in Q1 2026, and $625000.0 in Q4 2025.